Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.

被引：0
|
作者：
Myers, Andrea P.
Filiaci, Virginia L.
Zhang, Yuping
Pearl, Michael
Behbakht, Kian
Makker, Vicky
Hanjani, Parviz
Zweizig, Susan
Burke, James J.
Downey, Gordon
Leslie, Kimberly K.
Birrer, Michael J.
Fleming, Gini F.
机构：
[1] Novartis Inst Biomed Res, Cambridge, MA USA
[2] NRG Oncol, Buffalo, NY USA
[3] GOG Fdn Inc SDMC, Buffalo, NY USA
[4] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA
[5] Univ Hosp Stony Brook, New York, NY USA
[6] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[8] Weill Cornell Med Coll, New York, NY USA
[9] Abington Memor Hosp, Gladwyne, PA USA
[10] Univ Massachusetts Memor Hlth Care, Worcester, MA USA
[11] Mercer Univ, Sch Med, Savannah, GA USA
[12] Gynecol Oncol West Michigan, Grand Rapids, MI USA
[13] Massachusetts Gen Hosp, Dana Farber Canc Ctr, Boston, MA 02114 USA
[14] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.5592
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5592
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study
    Myers, Andrea P.
    Filiaci, Virginia L.
    Zhang, Yuping
    Pearl, Michael
    Behbakht, Kian
    Makker, Vicky
    Hanjani, Parviz
    Zweizig, Susan
    Burke, James J., II
    Downey, Gordon
    Leslie, Kimberly K.
    Van Hummelen, Paul
    Birrer, Michael J.
    Fleming, Gini F.
    GYNECOLOGIC ONCOLOGY, 2016, 141 (01) : 43 - 48
  • [2] Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: A gynecologic oncology group study
    Fleming, Gini F.
    Filiaci, Virginia L.
    Marzullo, Brandon
    Zaino, Richard J.
    Davidson, Susan A.
    Pearl, Michael
    Makker, Vicky
    Burke, James J., II
    Zweizig, Susan L.
    Van Le, Linda
    Hanjani, Parviz
    Downey, Gordon
    Walker, Joan L.
    Reyes, Henry D.
    Leslie, Kimberly K.
    GYNECOLOGIC ONCOLOGY, 2014, 132 (03) : 585 - 592
  • [3] Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study
    Fiorica, JV
    Brunetto, VL
    Hanjani, P
    Lentz, SS
    Mannel, R
    Andersen, W
    GYNECOLOGIC ONCOLOGY, 2004, 92 (01) : 10 - 14
  • [4] Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study
    Whitney, CW
    Brunetto, VL
    Zaino, RJ
    Lentz, SS
    Sorosky, J
    Armstrong, DK
    Lee, RB
    GYNECOLOGIC ONCOLOGY, 2004, 92 (01) : 4 - 9
  • [5] Phase II trial of combination bevacizumab and temsirolimus in the treatment of A recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study
    Alvarez, Edwin A.
    Brady, William E.
    Walker, Joan L.
    Rotmensch, Jacob
    Zhou, Xun C.
    Kendrick, James E.
    Yamada, S. Diane
    Schilder, Jeanne M.
    Cohn, David E.
    Harrison, Charles R.
    Moore, Kathleen N.
    Aghajanian, Carol
    GYNECOLOGIC ONCOLOGY, 2013, 129 (01) : 22 - 27
  • [6] Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study
    Alvarez, E.
    Brady, W.
    Walker, J.
    Rotmensch, J.
    Zhou, X.
    Kendrick, J.
    Yamada, S.
    Aghajanian, C.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S17 - S17
  • [7] A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study
    Bender, David
    Sill, Michael W.
    Lankes, Heather A.
    Reyes, Henry D.
    Darus, Christopher J.
    Delmore, James E.
    Rotmensch, Jacob
    Gray, Heidi J.
    Mannel, Robert S.
    Schilder, Jeanne M.
    Hunter, Mark I.
    McCourt, Carolyn K.
    Samuelson, Megan I.
    Leslie, Kimberly K.
    GYNECOLOGIC ONCOLOGY, 2015, 138 (03) : 507 - 512
  • [8] High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study
    Lentz, SS
    Brady, MF
    Major, FJ
    Reid, GC
    Soper, JT
    JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (02) : 357 - 361
  • [9] Evaluating traditional phase 2 trial design of systemic therapies in recurrent/advanced cervical cancer: A NRG Oncology/Gynecologic Oncology Group (GOG) ancillary data study.
    Gien, Lilian Tran
    Deng, Wei
    Thomas, Gillian
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: A Gynecologic Oncology Group (GOG) Study
    Aghajanian, C.
    Sill, M. W.
    Darcy, K.
    Greer, B.
    McMeekin, D. S.
    Rose, P. G.
    Rotmensch, J.
    Barnes, M. N.
    Hanjani, P.
    Leslie, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345